Therapeutic agent for Parkinson's disease

Details Therapeutic agent for Parkinson's disease Therapeutic agent for Parkinson's disease

1993-10-07

1996-01-16

Shah, Mukund J.

Organic compounds -- part of the class 532-570 series

Organic compounds

Chalcogen bonded directly to ring carbon of the purine ring...

544264, 544265, C07D47306, A61K 3152

Patent

active

054849209

ABSTRACT:
Agents for the treatment of Parkinson's disease contain, as an active ingredient, a xanthine derivative or a pharmaceutically acceptable salt thereof. The xanthine derivative is represented by the formula: ##STR1## in which R.sup.1, R.sup.2 are R.sup.3 are independently hydrogen, lower alkyl, lower alkenyl, or lower alkynyl; and R.sup.4 represents cycloalkyl, --(CH.sub.2).sub.n --R.sup.5 (in which R.sup.5 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group; and n is an integer of 0 to 4), or ##STR2## in which Y.sup.1 and Y.sup.2 represent independently hydrogen, halogen, or lower alkyl; and Z represents substituted or unsubstituted aryl, ##STR3## in which R.sup.6 represents hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro, or amino; and m represents an integer of 1 to 4, or a substituted or unsubstituted heterocyclic group; and X.sup.1 and X.sup.2 represent independently O or S.

REFERENCES:
patent: 2729642 (1956-01-01), Burgison
patent: 3624215 (1971-11-01), Stein et al.
patent: 3624216 (1971-11-01), Stein et al.
patent: 3641010 (1972-02-01), Schweiss et al.
patent: 3900474 (1975-08-01), Ginger et al.
patent: 4452788 (1984-06-01), Bristol et al.
patent: 4548820 (1985-10-01), Regnier et al.
patent: 4612315 (1986-09-01), Jacobson et al.
patent: 4696932 (1987-09-01), Jacobson et al.
patent: 4755517 (1988-07-01), Bruns et al.
patent: 4879296 (1989-11-01), Daluge et al.
patent: 4968672 (1990-11-01), Jacobson et al.
patent: 4981857 (1991-01-01), Daluge et al.
patent: 5098996 (1992-03-01), Jacobson et al.
patent: 5173491 (1992-12-01), Kamoun et al.
patent: 5175291 (1992-12-01), Kufner-Muhl
patent: 5248770 (1993-09-01), Jacobson et al.
Jacobson, K. A. et al. "Structure-Activity Relationships of 8-Styrylxanthines as A.sub.2 -Selective Adenosine Antagonists," J. Med. Chem. 36: 1333-1342, 1993.
Ossowska et al. Eur. J. Pharmacol., 182: 327-334, 1990.
Goodman, et al. In: Pharmacological Basis of Therapeutics, Gilman A. G. Ed. 8th Ed., Pergamon Press, N.Y., Chap. 20, 1990.
Erickson R. H. et al. "1,3,8-Trisubstituted Xanthines. Effects of Substitution Pattern upon Adenosine Receptor A.sub.1 /A.sub.2 Affinity". J. Med. Chem., 34, col. 1431-1435 (1991).
Kaupp, G. und Ringer, E. "Multifunktionelle Photoaddition von Stilben an Coffeinderivate und Benzothiazole." Chem. Ber., 119, col. 1525-1539 (1986).
Lugovkin, B. P. "Condensation of Isocaffeine-8-carboxaldehyde with Alkyl Iodides of Heterocyclic Bases." Chem. Abst., 60, col. 1741-1742 (1964).
Heikkila, et al. "Dopaminegeric Neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice", Science 224: 1451-1453 (1984).
Langston, et al. "Chronic Parkinsonism in humans due to a product of Meperidine-analog synthesis", Science 219: 979-980 (1983).
Jiang, et al. "Adenosine receptor antagonists potentiate dopamine receptor agonist--induced rotational behavior in 6-hydroxydopamine--lesioned rats", Brain Res. 613:347-351 (1993).

Affiliated with

Also associated with

Rating

Therapeutic agent for Parkinson's disease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic agent for Parkinson's disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic agent for Parkinson's disease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-310599